Abstract GS4-03: Neoadjuvant nab-paclitaxel weekly versus dose-dense paclitaxel followed by dose-dense EC in high risk HR+/HER2- early BC by: Results from the neoadjuvant part of ADAPT HR+/HER2- trial
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs20-gs4-03
Abstract: Background: Pathological complete response (pCR) is associated with improved outcome in patients with high-risk HR+/HER2- breast cancer (BC) but the use of (neo)adjuvant chemotherapy in early HR+/HER2- BC remains controversial. Oncotype DX / Recurrence Score… read more here.
Keywords: dose dense; high risk; risk her2; risk ... See more keywords